Inspire Medical Systems, Inc. (INSP)
NYSE: INSP · Real-Time Price · USD
92.23
-0.34 (-0.37%)
Dec 31, 2025, 4:00 PM EST - Market closed
Inspire Medical Systems Stock Forecast
Stock Price Forecast
The 16 analysts that cover Inspire Medical Systems stock have a consensus rating of "Buy" and an average price target of $137.63, which forecasts a 49.22% increase in the stock price over the next year. The lowest target is $85 and the highest is $216.
Price Target: $137.63 (+49.22%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inspire Medical Systems stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 2 | 2 | 3 | 3 |
| Buy | 7 | 5 | 6 | 6 | 7 | 8 |
| Hold | 3 | 6 | 7 | 8 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 14 | 15 | 16 | 15 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $89 → $91 | Hold | Maintains | $89 → $91 | -1.33% | Dec 23, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $125 → $175 | Buy | Maintains | $125 → $175 | +89.74% | Dec 17, 2025 |
| Mizuho | Mizuho | Buy Maintains $110 → $130 | Buy | Maintains | $110 → $130 | +40.95% | Dec 17, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $82 → $118 | Hold | Maintains | $82 → $118 | +27.94% | Dec 16, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $135 → $165 | Buy | Maintains | $135 → $165 | +78.90% | Dec 8, 2025 |
Financial Forecast
Revenue This Year
923.25M
from 802.80M
Increased by 15.00%
Revenue Next Year
1.03B
from 923.25M
Increased by 11.24%
EPS This Year
1.06
from 1.75
Decreased by -39.55%
EPS Next Year
1.77
from 1.06
Increased by 67.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 954.0M | 1.1B | ||||
| Avg | 923.3M | 1.0B | ||||
| Low | 882.0M | 977.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 18.8% | 20.7% | ||||
| Avg | 15.0% | 11.2% | ||||
| Low | 9.9% | 5.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.73 | 2.43 | ||||
| Avg | 1.06 | 1.77 | ||||
| Low | 0.43 | 1.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.0% | 129.3% | ||||
| Avg | -39.6% | 67.7% | ||||
| Low | -75.4% | 21.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.